SEC Form 4 · accession 0000874015-15-000078

IONIS PHARMACEUTICALS INC · IONS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

B Lynne Parshall

Officer — COO & Secretary · Director

Period of report

Oct 1, 2015

Accepted (ET)

Oct 5, 2015 · 7:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000874015

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Oct 1, 2015	M	4,162	$7.25	A	12,305	D
Common Stock^F1,F2	Oct 1, 2015	S	4,162	$40.1257	D	8,143	D
Common Stock^F1	Oct 1, 2015	M	2,838	$14.69	A	10,981	D
Common Stock^F1,F2	Oct 1, 2015	S	2,838	$40.1257	D	8,143	D
Common Stock^F1	Oct 2, 2015	M	2,000	$14.69	A	10,143	D
Common Stock^F1	Oct 2, 2015	S	2,000	$40.10	D	8,143	D
Common Stock^F1	Oct 2, 2015	M	3,436	$14.69	A	11,579	D
Common Stock^F1,F3	Oct 2, 2015	S	3,436	$42.3944	D	8,143	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (right to buy)^F4	$7.25	Oct 1, 2015	M	4,162	D	Jan 3, 2013	Jan 2, 2019	Common Stock	4,162	12,865	D
Employee Stock Option (right to buy)^F5	$14.69	Oct 1, 2015	M	2,838	D	Jan 2, 2014	Jan 29, 2020	Common Stock	2,838	34,790	D
Employee Stock Option (right to buy)^F6	$14.69	Oct 2, 2015	M	5,436	D	Jan 30, 2013	Jan 29, 2020	Common Stock	5,436	29,354	D

Explanation of responses

F1Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 2/11/2015.
F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.80 to $40.75, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.70, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
F4Grant of 1/3/2012 to reporting person of stock options under the Isis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/3/2013. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,437 shares per year. Following this transaction, the option was exercisable as to 7,719 on 10/1/2015.
F5Grant of 1/30/2013 to reporting person of stock options under the Isis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. Following this transaction, the option was exercisable as to 14,030 on 10/1/2015.
F6Grant of 1/30/2013 to reporting person of stock options under the Isis Pharmacueticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/2/2014. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 15,570 shares per year. Following this transaction, the option was exercisable as to 9,891 on 10/2/2015.